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ABSTRACT
Abstract: Rituximab (MabThera/Rituxan), a
chimeric murine/human monoclonal antibody
that binds specifically to the transmembrane
antigenCD20,was thefirst therapeuticantibodyto
enter clinical practice for the treatment of cancer.
As monotherapy and in combination with
chemotherapy, rituximab has been shown to pro-
long progression-free survival and, in some indi-
cations overall survival, in patients with various
B-cell malignancies, while having a well-estab-
lished and manageable safety profile and a wide
therapeutic window. As a result, rituximab is con-
sidered to have revolutionized treatment practices
for patients with B-cell malignancies. A subcuta-
neous (SC) formulation of rituximab has been
developed, comprising the same monoclonal
antibody as the originally marketed formulation
[rituximab concentrate for solution for intra-
venous (IV) infusion], and has undergone a
detailed, sequential clinical development pro-
gram. This program demonstrated that, at fixed
doses, rituximab SC achieves non-inferior serum
trough concentrations in patients with
non-Hodgkin lymphoma and chronic lympho-
cytic leukemia, with comparable efficacy and
safety relative to the IV formulation. The added
benefit of rituximab SC was demonstrated in ded-
icated studies showing that rituximabSCallows for
simplified and shortened drug preparation and
administration times resulting in a reduced treat-
ment burden for patients as well as improved
resource utilization (efficiency) at the treatment
facility. The improved efficiency of delivering
rituximab’s benefit to patients may broaden
patient access to rituximab therapy in areas with
low levels of healthcare resources, including
IV-chair capacity constraints. This article is a
companion paper to G. Salles, et al., which is also
published in this issue.
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INTRODUCTION
Rituximab (MabThera/Rituxan) was the first
therapeutic monoclonal antibody to enter
clinical practice for the treatment of cancer.
Engineered as a chimeric murine/human mon-
oclonal antibody, rituximab binds specifically
to the transmembrane antigen CD20, which is
present on the cell surface of pre-B lymphocytes
and mature B lymphocytes [1]. Since initial
marketing authorization in 1997, rituximab has
revolutionized the treatment of patients with
B-cell malignancies [cumulative patient-market
exposure in hematologic malignancies
1997–2016 was more than 4.4 million patients
(Roche data on file)] and is currently standard of
care for the common B-cell non-Hodgkin lym-
phomas (NHLs), follicular lymphoma (FL) and
diffuse large B-cell lymphoma (DLBCL), as well
as chronic lymphocytic leukemia (CLL) [2–5]. In
2015, rituximab was classified as an essential
medicine by the World Health Organization [6].
In FL, rituximab is given in combination
with chemotherapy to previously untreated
patients [7, 8] and forms the backbone of most
treatment regimens [5, 9]. It is also indicated for
maintenance therapy in FL and as monotherapy
for relapsed/refractory disease [7, 8]. Rituximab
is indicated in combination with chemotherapy
in first-line DLBCL [7, 8], with combinations
including cyclophosphamide, doxorubicin,
vincristine, and prednisolone (R-CHOP) being
the most common initial therapy [5, 10].
While FL and DLBCL both arise from B lym-
phocytes, the two diseases have distinct patholo-
gies, natural histories, prognoses, and standard
treatments. FL is an indolent lymphoma that arises
fromgerminal center B cells [9], whileDLBCL is an
aggressive, heterogeneous lymphoma of large B
cells that has a number of molecular subtypes,
including the germinal center B-cell (GCB) and
activated
B-cell (ABC) types [10]. FL is biologically hetero-
geneous, with a widely varying prognosis [9],
whereas DLBCL typically presents as an aggressive
lymphoma that evolves over months and leads to
symptomatic disease that would be imminently
fatal if left untreated [10]. Themajority of patients
with DLBCL can be cured with
immunochemotherapy, although those failing
R-CHOP induction generally succumb to their
disease. In the LNH-98.5 trial in 399 patients with
DLBCL, 10-year overall survival (OS) was 43.5% in
patients receiving R-CHOP and 27.6%with CHOP
alone [11]. Immunochemotherapy incorporating
rituximab is currently also a standard first-line
treatment for CLL, a clonal lymphoproliferative
disorder ofmature, peripheral B lymphocytes [12].
Rituximab in combination with chemotherapy is
indicated for the treatment of both previously
untreated and relapsed/refractory CLL [7, 8].
Numerous investigations have indicated that
rituximab’s anti-tumor activity is mediated via
several mechanisms, including antibody-de-
pendent cellular cytotoxicity, complement-de-
pendent cytotoxicity, induction of apoptosis,
and the phagocytosis of opsonized targets by
phagocytes, such as macrophages [1, 13–15]. In
addition to direct anti-tumor effects, rituximab
appears to work in synergy with other
chemotherapeutic agents, sensitizing tumor
cells to a variety of agents, including paclitaxel,
gemcitabine, bendamustine, cladribine, dox-
orubicin, and mitoxantrone [16–18].
Intravenous (IV) rituximab first gained reg-
ulatory approval in 1997 from the US Food and
Drug Administration (FDA) and in 1998 from
the European Medicines Agency (EMA) for use
in relapsed/refractory indolent NHL. Later this
approval was extended to include both induc-
tion treatment and maintenance treatment of
FL, treatment of DLBCL, as well as first-line and
relapsed/refractory CLL treatment. Clinical
studies supporting these indications have
shown that rituximab given as a single agent or
added to standard chemotherapy prolongs
progression-free survival (PFS) and, in some
indications, OS, in a spectrum of B-cell malig-
nancies [19–22], while having a well-established
and manageable safety profile [20–22] and a
wide therapeutic window [23–26].
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Rituximab was initially formulated for
administration via IV infusion, with infusions
typically administered over a period of 1.5–6 h
[7, 27]. The first infusion is usually the longest,
to minimize the risk of infusion-related reac-
tions (IRRs), with subsequent infusions being
given at slightly more rapid rates. IRRs are
reported by most patients during their first
infusion (77%) [7], but decrease substantially
with subsequent infusions, and cytokine release
syndrome accompanied by hypotension and
bronchospasm is reported in 10% of patients
[7]. In recent years, a 90-min infusion schedule
for second and subsequent infusions has proven
to be feasible and safe [27].
This review article summarizes the rationale
and key studies in the development of ritux-
imab SC. The information reported is derived
from previously conducted studies: this does
not include any new studies of human or ani-
mal subjects performed by any of the authors.
The Need for a Subcutaneous Formulation
While abbreviated IV infusion schedules can
help to reduce the time required to treat each
patient, IV infusions per se place a considerable
burden on patients and healthcare systems
alike, particularly in low- and middle-income
countries (LMICs). In these regions, patients
have restricted access to the healthcare resour-
ces needed to deliver labor-intensive anti-cancer
treatments, and less funding is available to
provide services and medications than in other
areas [28, 29].
As such, a rituximab formulation requiring
less time and fewer resources to administer
would have many advantages for patients and
healthcare systems, in both poorer and wealth-
ier countries. Such a formulation could improve
access to treatment, particularly where health-
care resources are limited, and could reduce the
burden of treatment and help to free up
healthcare provider capacity generally. With
this in mind, a rituximab SC injection, con-
taining the same active molecule as the stan-
dard rituximab IV infusion, was developed. The
aim was to simplify and shorten rituximab
administration to reduce the treatment burden
for patients as well as improve resource utiliza-
tion at the treatment facility, thereby facilitat-
ing more timely and increased access to this
important drug in resource-poor settings.
Rituximab SC is now approved for use in the EU
[March 2014 (NHL), May 2016 (CLL)] and USA
(June 2017) for the treatment of patients with




Establishing the SC route of administration for
rituximab was not possible using the existing IV
formulation, because the volumes required to
achieve therapeutic levels exceed tolerable
thresholds [33]. Therefore, a new rituximab
formulation was needed to facilitate SC
administration. To reduce the injection volume,
the SC solution was concentrated 12-fold (to
120 mg/ml) relative to the IV formulation
[33, 34]. Even at this concentration, however,
the volume required was still prohibitive for SC
injection. Rituximab was therefore co-formu-
lated with recombinant human hyaluronidase
(rHuPH20), an enzyme used to increase the
dispersion and absorption of co-administered
substances when given subcutaneously [7].
rHuPH20 achieves this by transiently depoly-
merizing interstitial hyaluronan at the injection
site, resulting in decreased resistance to fluid
flow and increased dispersion and absorption of
injected medicines and fluids, and allowing the
injection of volumes which would otherwise be
too large for SC administration with limited
swelling or pain [35]. rHuPH20 is long estab-
lished as a permeating agent in palliative care,
with rapid and localized action, no systemic
distribution and no long-term effects on tissue
[36]. rHuPH20 has been shown to be well tol-
erated, with no allergic reactions occurring in
healthy volunteers who were injected intrader-
mally [37]. Furthermore, no interactions
between rituximab and rHuPH20 in the ritux-
imab SC drug product were identified during
the development program (Roche Data on File).
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Scientific Rationale
The rituximab SC development program was
founded on the knowledge and experience
accumulated with rituximab in clinical practice
and based on the scientific consideration that
serum rituximab levels at least as high as those
achieved after IV infusion would result in at
least the same degree of target-site saturation
and, as a result, provide the same degree of
efficacy, regardless of the administration route
[34, 38]. Therefore, a pharmacokinetic
(PK)-based clinical bridging program was
undertaken, aimed at achieving PK non-inferi-
ority of rituximab SC relative to the established
IV dosing regimens for NHL and CLL and eval-
uating whether a change in administration
route has an impact on the anti-B-cell activity
and safety profile of rituximab in the treatment
of FL, DLBCL, and CLL. Based on the fact that
the monoclonal antibody in both rituximab
formulations was identical, the development
program aimed to demonstrate PK non-inferi-
ority of rituximab SC relative to rituximab IV
and provide supportive evidence of comparable
clinical outcomes to validate the PK-bridging
approach and support extrapolation to the full
range of oncology indications established for
rituximab.
Pharmacokinetic Considerations
The primary PK endpoint used in clinical
bridging was the rituximab serum trough con-
centration (Ctrough). Ctrough was selected as the
most appropriate measure of exposure to bridge
rituximab IV to SC because it reflects the mini-
mum concentration of rituximab during a
respective dosing interval, which is available for
binding to the target and therefore can be used
as a reference to maintain target saturation of B
cells to achieve the desired pharmacodynamic
(PD) effect and clinical efficacy. By ensuring
non-inferior serum rituximab Ctrough after SC
injection relative to IV administration, tar-
get-receptor occupancy would be maintained
and therefore the same degree of anti-B-cell
activity was expected.
AUC was chosen as the secondary PK end-
point because this parameter provides infor-
mation on exposure during the entire treatment
cycle and, like Ctrough, correlates with response
[39, 40]. Cmax was not considered an appropri-
ate PK parameter when comparing the IV and
SC routes of administration since the inherent
kinetics are different: Cmax via the IV route is
instantaneous at the end of the infusion and is
an arbitrary measure before equilibration occurs
between the different blood, tissue, and lym-
phatic compartments, whereas Cmax via the SC
route is achieved in approximately 3 days [7, 8],
i.e., there is additional time in which tar-
get-specific elimination [41] could potentially
affect Cmax. The fact that target-specific elimi-
nation does not affect Cmax after IV infusion
may also explain why Cmax does not correlate
with response [39].
In developing a new dosage form of ritux-
imab for SC administration, a switch from body
surface area (BSA)-adjusted dosing to fixed (flat)
dosing was considered to simplify drug prepa-
ration (ready-to-use formulation, reducing
wastage) and to reduce the potential risk of
dosing errors. The use of body-size-adjusted
dosing in oncology is largely historical and
based on many years of experience with
chemotherapeutic agents that have a narrow
therapeutic window. However, monoclonal
antibodies such as rituximab (the first to be
approved for treatment of lymphoma) have a
wide therapeutic window, and therefore it is
possible to adopt a different approach. Fixed
dosing was explored for rituximab SC based on
a published simulation study of 12 monoclonal
antibodies including rituximab, which showed
that the variability in PK would be no greater
with a fixed-dose approach than with a
body-size-adjusted dosing approach [42].
In moving from BSA-adjusted dosing with
rituximab IV to fixed dosing with rituximab SC,
differences in exposure were expected across the
treated population, with a trend toward a rela-
tively lower exposure in patients with a high
BSA and a relatively higher exposure in patients
with a low BSA. Consequently, the selected
fixed dose of rituximab SC needed to be high
enough to provide sufficient drug exposure over
the entire BSA range to ensure clinical benefit in
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patients with high BSA, while maintaining an
acceptable safety profile in patients with low
BSA. Given the wide therapeutic window of
rituximab, it was considered unlikely that dif-
ferences in exposure expected after SC admin-
istration compared with IV administration
would result in a greater risk of adverse
reactions.
PRE-CLINICAL STUDIES
Initial studies comparing the IV and SC formu-
lations of rituximab were conducted in mice
[34] and cynomolgus monkeys [43]. These
investigations provided the first evidence that
rituximab SC had similar PK, PD, and anti-tu-
mor activity to the IV formulation. A human
tumor xenograft model (severe combined
immunodeficiency mice transplanted with the
Z138 mantle cell lymphoma cell line) showed
similar Ctrough values and a comparable reduc-
tion in tumor size across three dose levels of
rituximab SC and IV [34]. In cynomolgus
monkeys, comparable Ctrough concentrations
were achieved following rituximab IV and SC
administration; this was accompanied by
equivalent PD effects (i.e., target B-cell deple-
tion in the peripheral circulation and distant
lymph nodes) [43]. Subsequently, similar PD
effects were seen in the SABRINA study (Fig. 1,
44).
CLINICAL STUDIES
A stepwise approach was adopted to select and
confirm the rituximab SC doses in NHL and CLL
across the three PK-bridging clinical develop-
ment studies in terms of non-inferior Ctrough
relative to rituximab IV and to investigate the
effect of the administration route on the anti
B-cell activity and safety profile of rituximab
(Fig. 2; Table 1).
Pharmacokinetic Studies: Dose Finding
Non-Hodgkin Lymphoma
The first clinical study conducted using the new
SC formulation of rituximab was the phase Ib
SparkThera study (Table 1), [45]. SparkThera
investigated the PK, safety, and tolerability of
rituximab SC in patients with FL. The two-part
study was conducted in the FL maintenance
setting following an adequate response to
induction therapy and at least one cycle of
rituximab IV monotherapy in maintenance.
Patients were thus harmonized by the fact that
they had all achieved at least a partial response
(PR) to rituximab-containing induction therapy
(with or without chemotherapy). The patients’
low tumor burden and B-cell-depleted status
upon entering the study made them an optimal
population for the study of PK parameters with
minimal effects of target-specific rituximab
elimination, which could potentially confound
comparison of the PK profiles of the different
routes of administration. PK variability was
expected to be low, resulting in a patient pop-
ulation with adequate homogeneity to investi-
gate the PK parameters of rituximab
administered either directly into the systemic
circulation (IV) or via absorption from the SC
tissue.
The objective of the SparkThera study was to
determine a SC dose that would yield a ritux-
imab Ctrough concentration in the same range as
that achieved with rituximab IV at the standard
dose of 375 mg/m2 across the clinically estab-
lished dosing intervals as well as to select a
Fig. 1 Time-time curve of B-cell depletion in SABRINA
[44, data on file]
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starting dose for the CLL dose-finding part of
the SAWYER study (see below). Patients with FL
who had achieved at least a PR following
rituximab-based induction therapy, and had
received at least one dose of IV rituximab as
maintenance therapy, were given a single dose
of either rituximab SC (375, 625, or 800 mg/m2)
or rituximab IV (375 mg/m2) as part of their
maintenance therapy schedule. After the single
dose, all patients continued with rituximab IV
until they had completed 2 years of mainte-
nance. PK modeling based on data from stage 1
was then used to determine a fixed dose of
rituximab SC that would result in non-inferior
Ctrough and comparable AUC to that achieved
with rituximab IV at 375 mg/m2, regardless of
BSA and whether rituximab was given every 2 or
3 months. A dose of 1400 mg was selected for
assessment in stage 2 to ensure that all patients,
including those at the upper end of the BSA
range, would achieve sufficiently high Ctrough
levels so that under-dosing did not occur.
Chronic Lymphocytic Leukemia
The first study of rituximab SC in patients with
CLL was the phase 1b, two-part SAWYER study
[46]. In the dose-finding stage, patients with
previously untreated CLL received five cycles of
rituximab IV in combination with fludarabine
and cyclophosphamide (FC), followed by a sin-
gle dose of rituximab SC given at one of three
dosing levels: 1870 (initially predicted by data
from the SparkThera trial), 1400, or 1600 mg. As
in SparkThera, the primary objective of this
stage was to identify a fixed SC dose that would
achieve comparable rituximab Ctrough levels to
those achieved with the established IV dose
(500 mg/m2, 4 weekly). The resulting PK data
were applied to a population PK model, which
predicted that a fixed SC dose of 1600 mg would
achieve non-inferior Ctrough values to 4-weekly
rituximab IV at 500 mg/m2 (i.e., the clinically
established rituximab dose and dosing interval
for CLL).
Fig. 2 Overview of the clinical development of rituximab.
SC dose-finding/confirmation and efficacy studies, AUC
area under the concentration-time curve, CI confidence
interval, CRR complete response (CR/CRu) rate; Ctrough,
trough or minimum serum concentration, CTSQ cancer
treatment satisfaction questionnaire, GMR geometric
mean ratio, INV investigator, IRC independent review
committee, ORR overall response rate, PPQ patient
preference questionnaire, RASQ rituximab administration
satisfaction questionnaire



























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Two studies in patients with NHL confirmed
Ctrough non-inferiority for rituximab SC at the
chosen fixed dose relative to the standard
rituximab IV dose: SparkThera stage 2 and
SABRINA stage 1. In SparkThera stage 2, 154
additional patients who had achieved at least
PR following induction and had received at least
one dose of rituximab IV as monotherapy in
maintenance were randomized to receive either
the fixed 1400 mg SC dose determined using
data from stage 1 or the standard rituximab IV
dose of 375 mg/m2, both given at 2- or 3-month
intervals until 2 years of maintenance had been
completed [45]. The study confirmed that
Ctrough levels following a fixed SC dose of
1400 mg rituximab were non-inferior to the
Ctrough levels achieved with rituximab IV at
375 mg/m2, when given at either 2- or 3-month
intervals [Table 2].
SABRINA was a two-stage randomized,
open-label, phase III study of rituximab given in
combination with either cyclophosphamide,
vincristine and prednisone (CVP) or CHOP
chemotherapy to previously untreated patients
with FL. Patients received one induction dose of
rituximab IV, followed by either SC (1400 mg)
or IV (375 mg/m2) rituximab once every 3 weeks
at cycles 2–8 [44, 47]. Patients with a complete
response (CR) or PR following induction ther-
apy continued IV or SC maintenance rituximab
every 8 weeks. The primary endpoint assessed
for stage 1 was the ratio of observed rituximab
Ctrough between the SC and IV groups at
induction cycle 7 (i.e., before dosing cycle 8).
The last Ctrough value of the induction dosing
interval was chosen to minimize the effects of
target-specific elimination of rituximab when
assessing the effects of a change in administra-
tion route on PK. At the end of induction cycle
7, the geometric mean for rituximab Ctrough was
higher in the SC group than in the IV group
(Table 2), and the lower limit for the two-sided
90% confidence interval of the SC to IV geo-
metric mean ratios exceeded the prespecified
margin of 0.8, confirming Ctrough non-inferior-
ity of rituximab SC to IV.
Chronic Lymphocytic Leukemia
In part 2 of the SAWYER study, a separate group
of previously untreated patients with CLL
received induction treatment with FC, plus
either a fixed 1600 mg dose of rituximab SC or
500 mg/m2 rituximab IV every 4 weeks for up to
six cycles [48]. In cycle 1, all patients received
rituximab IV at 375 mg/m2. At the end of cycle
5, the geometric mean Ctrough in patients given
rituximab SC was non-inferior to that in
patients given rituximab IV (Table 2), thus
confirming non-inferiority of the chosen SC
dose relative to the standard IV dose. In addi-
tion, AUC data at cycle 6 indicated that expo-
sure was at least as high after rituximab SC as
after IV dosing (Table 2).
Notably, the high BSA subgroup in the
SAWYER study had mean Ctrough and AUC val-
ues after administration of rituximab SC that
were at least as high as those following IV
administration of rituximab, a finding that was
also replicated in NHL patients with high BSA in
the SABRINA [47] and SparkThera studies [45].
Together these findings demonstrate that the
selected doses of rituximab SC 1400 and
1600 mg for NHL and CLL, respectively, result
in adequate exposure across all BSA subgroups
and at least the same exposure compared with
the standard rituximab IV doses and dosing
intervals in these settings.
Clinical Studies Confirming the Efficacy
of Subcutaneous Rituximab
Non-Hodgkin Lymphoma
Two large phase III studies, SABRINA and
MabEase, were conducted to investigate whe-
ther SC administration impacts the anti-lym-
phoma activity of rituximab (Fig. 2) [44, 47, 49].
After stage 1 had confirmed the Ctrough
non-inferiority of rituximab SC, stage 2 of the
SABRINA study enrolled 283 additional patients
who were randomized to the same treatment
and schedules as in stage 1 (Table 1). The
objectives of stage 2 included providing addi-
tional efficacy data and estimating response
rates at the end of induction [44]. In the
pre-planned pooled analysis, the overall
response (OR) rate at the end of induction was
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84.4% in the rituximab SC group and 84.9% in
the IV group (Table 3), while CR/unconfirmed
CR (CRu) rates were 32.2% for rituximab SC and
32.2% for rituximab IV. ORR at the end of
maintenance was 77.9% [95% confidence
interval (CI) 71.0–83.9] in the SC group and
Table 2 Summary of Ctrough and AUC data from pharmacokinetic analyses in the SparkThera (follicular lymphoma),
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AUC area under the concentration-time curve, CI confidence intervals, Ctrough trough serum concentration, IV intravenous, q2 m every 2 months,
q3 m every 3 months, q3w every 3 weeks, q4w every 4 weeks, SC subcutaneous
a Predicted
b Coefficient of variation
c Geometric mean ratio adjusted for tumor load at baseline
d AUC over the dosing interval tau
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78.1% (95% CI 71.3–83.9) in the IV group [44].
Response rates were also comparable across
patient subgroups, including gender and body
surface area (Fig. 3). At a median follow-up of
37 months, there was no substantial difference
between rituximab SC and IV in terms of PFS
[hazard ratio (HR) 0.84, 95% CI 0.57–1.23]
(Fig. 4a), event-free survival (HR 0.91, 95% CI
0.64–1.31), or OS (HR 0.81, 95% CI 0.42–1.57).
Furthermore, the stage 1 and 2 pooled geomet-
ric mean Ctrough data were consistent with the
SABRINA and SparkThera stage 1 results and
indicate that the subcutaneous dose of 1400 mg
rituximab is non-inferior to a 375 mg/m2
intravenous dose of rituximab over the entire
treatment course during the induction phase
when given every 3 weeks in combination with
chemotherapy and during single agent treat-
ment every 2 months for a duration of 2 years
(Fig. 4b).
The open-label MabEase study examined
whether there were any major efficacy differ-
ences between rituximab SC and IV in DLBCL.
Patients with previously untreated DLBCL were
randomized to receive one cycle of rituximab IV
375 mg/m2 followed by an additional seven
cycles of either 1400 mg rituximab SC or
375 mg/m2 rituximab IV, plus six or eight cycles
of CHOP every 14 or 21 days (Table 1), [49]. The
CR/CRu rate at the end of induction treatment
for the intent-to-treat (ITT) population was
similar for the two treatment groups (51% vs.
42% for rituximab SC vs. rituximab IV, respec-
tively) (Table 3). After a median follow-up of
35 months, median survival in the ITT popula-
tion was not reached for PFS, EFS, or OS [49].
Chronic Lymphocytic Leukemia
The secondary endpoint of clinical response in
the SAWYER study (stage 2) indicated similar
response rates between the rituximab SC and IV
treatment groups, which supports the findings
in NHL. OR rates 3 months after treatment
completion were 85% and 81% for the ritux-
imab SC and IV groups, respectively. CR rates
were 26% and 33% [48].
In summary, given the established Ctrough
non-inferiority of rituximab SC, the efficacy
results of the SABRINA, MabEase, and SAWYER
studies consistently demonstrate that switching
to the SC route of administration does not
impair the anti-B-cell activity of rituximab.
Safety and Tolerability of Subcutaneous
Administration
Rituximab IV is generally well tolerated with a
well-defined safety profile [50]. The most
Table 3 Summary of response rates (investigator-assessed; intent-to-treat population) from SABRINA (follicular lym-
phoma), MabEase (diffuse large B-cell lymphoma), and SAWYER (chronic lymphocytic leukemia) studies [44, 48]
Study Treatment group n Response rate (%) (95% CIa)
Completeb Partial Overall








MabEasec R(SC) ? CHOP















CHOP cyclophosphamide, doxorubicin, vincristine, prednisolone, FC fludarabine and cyclophosphamide, IV intravenous,
R rituximab, SC subcutaneous
a Where available
b Includes complete response confirmed and complete response unconfirmed
c Response rates at end of induction
d Response rates 3 months after treatment completion
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common adverse events in patients treated with
rituximab IV are infusion-related reactions,
including cytokine release syndrome and tumor
lysis syndrome, and general hypersensitivity
reactions such as fever, chills, rigors, hypoten-
sion, urticaria, and angioedema [7]. These are
reported by the majority of patients during their
first infusion [7], but decrease substantially with
subsequent infusions. Notably, in the clinical
development studies, rituximab was always
administered IV during the first treatment cycle
to maintain the option of slowing down or
stopping the infusion in case of the develop-
ment of IRRs. Other common adverse events
associated with rituximab include pruritus,
nausea, vomiting, headaches, fever, neutrope-
nia, and infections.
Fig. 3 OR rate by BSA category (a) [Adapted from Davies
et al. 2017] [44] and gender (b) [67] at the end of
induction in SABRINA. CI confidence interval, CR
complete response, BSA body surface area, IV intravenous,
SC subcutaneous Part A reproduced from The Lancet
Haematology, vol. 4, Davies A, Merli F, Mihaljević B, et al.
Efficacy and safety of subcutaneous rituximab versus
intravenous rituximab for first-line treatment of follicular
lymphoma (SABRINA): a randomised, open-label, phase 3
trial, e272–82, Copyright (2017), with permission from
Elsevier
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In the SC clinical development program in
over 1500 patients, rituximab SC was well tol-
erated with an overall safety profile similar to
that of the IV formulation and no unexpected
safety signals. The adverse events reported for
rituximab SC were similar to those reported
with rituximab IV, with the exception of an
increase in the incidence of mostly
mild-to-moderate administration-related reac-
tions (ARRs) and local cutaneous reactions
reflecting the expected safety profile of subcu-
taneously administered drugs [44, 45, 48–52].
Fig. 4 Progression-free survival in patients receiving ritux-
imab SC or IV in a the phase III SABRINA study [44].
b Geometric mean ratio non-inferiority of rituximab SC
versus IV in SABRINA. CI confidence interval, HR hazard
ratio. For time-to-event analyses, a hazard ratio below 1
implies a risk reduction for rituximab SC. Reproduced
from The Lancet Haematology, Vol. 4, Davies A, Merli F,
Mihaljević B, et al. Efficacy and safety of subcutaneous
rituximab versus intravenous rituximab for first-line
treatment of follicular lymphoma (SABRINA): a ran-
domised, open-label, phase 3 trial, e272–82, Copyright
(2017), with permission from Elsevier
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Furthermore, as with the IV formulation, the
frequency and intensity of SC-related ARRs
decreased with subsequent rituximab SC
administration. In a recent retrospective review
of case notes (51 patients) from a single insti-
tution, rituximab SC was safely administered
without antipyretic/antihistamine pre-medica-
tion. Among 307 doses of rituximab SC (pa-
tients had previously received rituximab IV
cycle 1 with prophylaxis as specified in the
prescribing information), two adverse events
were noted, local skin reaction (n = 1) and
myalgia (n = 1) [53].
In the SABRINA study, where rituximab was
administered in combination with chemother-
apy, 96% (rituximab SC) and 95% (rituximab
IV) of patients experienced an adverse event,
respectively [44]. Grade C3 adverse events
occurred in a similar proportion of patients (SC:
56%; IV: 55%). The most common any-grade
adverse events were (SC vs. IV) neutropenia
(32% vs. 27%), nausea (31% vs. 22%), consti-
pation (25% vs. 26%), cough (23% vs. 13%),
fatigue (20% vs. 18%), diarrhea (18% vs. 16%),
asthenia (17% vs. 13%), paresthesia (16% vs.
12%), pyrexia (15% vs. 16%), anemia (15% vs.
13%), and upper respiratory tract infection
(15% vs. 10%). Neutropenia (26% vs. 21%) was
the most common grade C3 adverse event.
Similar grade C3 (58% SC vs. 54% IV) adverse
event rates were reported in the MabEase study
(patients with DLBCL) [49]. Grade 3/4 febrile
neutropenia was more frequent in the SC arm
(12.5% vs. 6.9%, p = 0.0575). Injection-site
reactions were reported by 5.7% of patients in
the SC arm compared with no patients in the IV
arm.
Patients with CLL show a similar pattern.
Proportions of patients reporting adverse events
of any grade were 96% for SC and 91% for IV in
the SAWYER trial [48]. The most common
grade C3 adverse event was neutropenia (56%
SC and 52% IV); the most common serious
adverse event was febrile neutropenia (11% SC
and 4% IV). ARRs were reported in 44% of SC
and 45% of IV patients. More patients reported
local cutaneous reactions after rituximab SC
(42% versus 2%); most of these reactions were
grade 1–2.
ARRs were commonly experienced following
both IV and SC dosing in an ongoing phase IIIb
study (MabCute) investigating the efficacy and
safety of rituximab SC maintenance until dis-
ease progression in patients with NHL [52]. In
this study, all patients receive one cycle of
rituximab IV followed by rituximab SC in sub-
sequent cycles of induction and maintenance
(Table 1). The overall safety profile was similar
to that seen in previous trials, with neutropenia,
nausea, and pyrexia the most common adverse
events. In total, 28% of patients experienced an
ARR after one dose of rituximab IV, while 41%
of patients had reported an ARR after a median
of five cycles of rituximab SC. The phase IIIb
MabRella safety study is specifically investigat-
ing ARRs following multiple doses of rituximab
SC in combination with chemotherapy for the
first-line or maintenance treatment of patients
with NHL (Table 1) [54]. Preliminary results
indicate an overall safety profile in keeping with
previous reports, with neutropenia, asthenia,
erythema, and pyrexia the most common
adverse events. Overall, 22% of patients expe-
rienced an ARR, with erythema (10%) and
injection site erythema (4%) being the most
common.
Reassuringly, adverse event rates have been
similar for rituximab IV and SC administration
in patients with low, medium, and high BSA
[44, 45], suggesting that fixed-dose administra-
tion does not increase toxicity in low BSA
patients, in whom antibody exposure may be
greater relative to the exposure after rituximab
IV BSA-adjusted dosing. The lack of increased
toxicity after greater exposure was expected, as
the exposure after BSA-adjusted dosing results
in near complete target site saturation, and in
that context there is a low probability of surplus
rituximab IgG monoclonal antibodies not
binding to their target to cause additional
toxicity.
Rituximab SC is therefore well tolerated,
with an adverse event profile similar to ritux-
imab IV. Data from the post-marketing setting,
which included over 34,000 patients exposed to
rituximab SC as of September 2016 (data on
file), were consistent with clinical trial
experience.
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BENEFITS OF SUBCUTANEOUS
ADMINISTRATION
Reduced Treatment Burden for Patients
The burden of cancer treatment is felt across all
demographics and in all countries. By simplify-
ing and shortening rituximab preparation and
administrationwithSCdosing, itwas anticipated
that rituximab SC would reduce the treatment
burden for patients, as has been shown for tras-
tuzumab [33, 55]. The much shorter preparation
and delivery time of rituximab SC versus IV
reduces the time required for patients to be pre-
sent in the clinic, which has implications for
resource utilization (see later). In addition,
rituximab SC given in combination with other
SC or oral chemotherapeutics, or as single-agent
maintenance, would eliminate the need for
central venous access. The potential for reduc-
tion of burden of cancer treatment is consider-
able, and studies suggest that this is indeed the
case, with patients preferring rituximab SC for its
convenience and reduced impact on their lives.
In a prospective, randomized, open-label,
crossover study investigating patient preference
for rituximab SC or IV in patients with previ-
ously untreated DLBCL or FL (PrefMab study),
77–84% of patients expressed a preference for
rituximab SC at cycle 8 [Fig. 5; 51]. The most
commonly identified reasons for preference for
rituximab SC were ‘‘requires less time in the
clinic,’’ ‘‘feels more comfortable during admin-
istration,’’ and ‘‘feels less emotionally distress-
ing’’ (Fig. 5). Preference was assessed using a
Patient Preference Questionnaire that recorded
SC, IV, or no preference and rated preference on
a three-point scale, as well as asking patients to
report two main reasons for their preference.
Furthermore, rituximab SC was associated
with higher scores than rituximab IV on a
rituximab-specific treatment satisfaction ques-
tionnaire that rated various aspects of treatment
on a 0–100 scale: patient satisfaction (88 vs. 75),
impact on activities of daily living (83 vs. 58),
and convenience (83 vs. 58). Median adminis-
tration time per cycle has been shown to be
substantially lower for SC than IV dosing: 6 min
versus 170–240 min. Patients participating in
theMabCute study expressed similar satisfaction
and preference for rituximab SC [56], as did
patients participating in the MabEase study [57].
Interestingly, the PrefMab study found that
scores for the ‘psychologic impact’ domain of the
rituximab-specific questionnaire were similar for
both rituximab SC and IV (88 vs. 80) [51]. On the
one hand, the shorter administration times asso-
ciated with rituximab SC may lead to a lower
psychologic impact as a result of spending less
time in a clinic attached to an IV line, observing
other patients receiving their infusions, and
potentially, experiencing adverse events. Con-
versely, IV administration may increase patient
support and wellbeing as a result of the closer
supervision and prolonged contact occurring
between patients and healthcare professionals
during extended clinic visits. Notably, a similar
proportionof patients in the SCand IV armsof the
MabEase study reported that rituximab adminis-
tration didnot affect the amount of time available
for them to talk to adoctor ornurse (81%vs. 82%),
suggesting that the shorter infusion time does not
interfere with patients’ ability to discuss their ill-
ness with a healthcare professional [57].
Improved Resource Utilization
Numerous studieshave investigated the impact of
SC administration of rituximab on healthcare
resource utilization [48, 57–60]. In time and
motion studies, rituximab SCwas associated with
a reduction in active healthcare professional time
spent on the preparation and administration of
rituximab, a consequent reduction in human
resource-related costs, and a reduction in the
cFig. 5 Findings from the PrefMab study showing an
overall patient preference for the SC or IV route of
rituximab administration at cycles 6 and 8; b strength of
patient preference for the SC or IV route; c reasons for
patient preference in patients preferring SC administration
[51]’. Figure reproduced from Rummel M, Kim TM,
Aversa F, et al. Preference for subcutaneous or intravenous
administration of rituximab among patients with untreated
CD20? diffuse large B-cell lymphoma or follicular lym-
phoma: results from a prospective, randomised, open-label,
crossover study (PrefMab). Ann Oncol. 2017;28:836–42,
by permission of Oxford University Press
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amount of time patients spent in the treatment
room compared with rituximab IV [58, 59].
As noted earlier, median administration time
for rituximab SC is 6 min (substantially lower
than for rituximab IV: 170–240 min). In the
time and motion study that accompanied
MabCute, mean active healthcare professional
(HCP) time was significantly reduced from 35.0
to 23.7 min when rituximab was administered
SC rather than IV (-32% difference; p\0.0001)
[59]. The active HCP time was time (stopwatch)
actively dedicated by any staff member on pre-
specified tasks in the treatment room and drug
preparation area. In addition, mean patient
time spent in the treatment chair was signifi-
cantly shorter with rituximab SC (67.3 min)
compared with rituximab IV (262.1 min;
p\0.0001). The authors calculated that an
average 3.5 patients could be treated with
rituximab SC (first session IV and 10 sessions
SC) for every patient treated IV, a finding that
has important resource utilization and eco-
nomic implications. An Italian hospital-based
survey reported that rituximab SC resulted in
resource and cost savings compared with ritux-
imab IV, including reduced drug wastage [60].
In the SAWYER study, both physicians and
nurses reported time savings for SC compared
with IV administration, and the majority
reported that rituximab SC was more conve-
nient than rituximab IV [48].
These findings suggest that the impact of
rituximab SC on healthcare systems worldwide
may be substantial. With the therapeutic land-
scape in hematology evolving toward
chemotherapy- and IV-free treatment regimens,
administering a key agent like rituximab via a
non-IV route would allow for simplified and
shortened drug administration and preparation
times, leading to reduced treatment burden for
patients and improved resource utilization at
the treatment facility.
CONCLUSIONS
The sequential clinical development program
utilizing PK and clinical bridging has clearly
demonstrated that rituximab SC results in
rituximab exposures at least as high as those
achieved with rituximab IV. Furthermore,
rituximab SC has comparable clinical efficacy
and safety to rituximab IV, with the advantage of
a reduced treatment burden for patients as well
as improved healthcare resource utilization.
Rituximab SC is supplied as a ready-to-use for-
mulation, allowing preparation and administra-
tion of rituximab therapy within minutes, with
no compounding required. Administration of
rituximab SC takes considerably less time than
rituximab IV, and the fixed- rather than
BSA-based dosing potentially reduces the risk of
dosing errors and spillage of the IV infusionfluid.
For patients with poor venous access, rituximab
SC offers an alternative route of administration
and may also reduce the risk of catheter-related
sepsis if a central venous catheter is no longer
required. Increased rates of localized injection
site reactions with SC administration have been
reported in clinical studies, but these events have
been manageable and consistent with expected
changes when switching from IV to SC dosing
and tend to decrease in frequency and intensity
as treatment progresses.
Recognizing the burden of IV infusions on
both healthcare systems and patients, the thera-
peutic landscape in hematology is evolving
toward treatment that is chemotherapy-free and
based increasinglyonnon-IV targetedagents [61],
which may eliminate the need for central venous
access altogether. Several orally administered
therapeutics, including ibrutinib, idelalisib, and
venetoclax, have recently been approved for use
in B-cell malignancies, either as monotherapy or
in combination with rituximab or other agents,
andmany chemotherapy regimensmay now also
be administered orally [62–66].
Rituximab SC therefore offers a more effi-
cient delivery of rituximab’s recognized clinical
benefit with less treatment-related burden for
patients. The new formulation provides equiv-
alent efficacy and safety to rituximab IV with
greater convenience and improved patient sat-
isfaction and time (and potentially cost) saving.
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safety of rituximab subcutaneous versus intra-
venous in first-line follicular lymphoma: the ran-
domised, open-label, phase III SABRINA study.
Lancet Haematol. 2017. doi:10.1016/S2352-
3026(17)30078-9 (epub ahead of print).
45. Salar A, Avivi I, Bittner B, et al. Comparison of
subcutaneous versus intravenous administration of
rituximab as maintenance treatment for follicular
lymphoma: results from a two-stage, phase IB
study. J Clin Oncol. 2014;32:1782–91.
46. Assouline S, Buccheri V, Delmer A, et al. Pharma-
cokinetics and safety of subcutaneous rituximab
plus fludarabine and cyclophosphamide for
patients with chronic lymphocytic leukaemia. Br J
Clin Pharmacol. 2015;80:1001–9.
47. Davies A, Merli F, Mihaljevic B, et al. Pharmacoki-
netics and safety of subcutaneous rituximab in fol-
licular lymphoma (SABRINA): stage 1 analysis of a
randomised phase 3 study. Lancet Oncol.
2014;15:343–52.
48. Assouline S, Buccheri V, Delmer A, et al. Pharma-
cokinetics, safety, and efficacy of subcutaneous
versus intravenous rituximab plus chemotherapy as
treatment for chronic lymphocytic leukaemia
(SAWYER): a phase 1b, open-label, randomised
controlled non-inferiority trial. Lancet Haematol.
2016;3:e128–38.
49. Lugtenburg P, Avivi I, Berenschot H, et al. Efficacy
and safety of subcutaneous and intravenous ritux-
imab plus cyclophosphamide, doxorubicin, vin-
cristine, and prednisone in first-line diffuse large
B-cell lymphoma: the randomized MabEase study.
Haematologica. 2017 (in press).
50. Kimby E. Tolerability and safety of rituximab
(MabThera). Cancer Treat Rev. 2005;31:456–73.
51. Rummel M, Kim TM, Aversa F, et al. Preference for
subcutaneous or intravenous administration of
rituximab among patients with untreated CD20?
diffuse large B-cell lymphoma or follicular lym-
phoma: results from a prospective, randomised,
open-label, crossover study (PrefMab). Ann Oncol.
2017;28:836–42.
52. Rule S, Briones J, Carella AM, et al. Extending sub-
cutaneous rituximab maintenance therapy from
2 years until progression versus observation in
patients with indolent non-Hodgkin’s lymphoma:
interim safety data from the MABCUTE study.
Blood 2013;122. (ASH annual meeting abstracts,
abstract 3052).
53. Burrows SH, Akinbobuyi O, Rule S, Crosbie N.
Subcutaneous rituximab can be safely administered
without pre-medication. Br J Haematol. 2017.
doi:10.1111/bjh.14703 (epub ahead of print).
54. Panizo C, Bekadja MA, Meddeb B, et al. Safety of
subcutaneous administration of rituximab during
the first-line treatment of patients with
non-Hodgkin lymphoma: the MabRella study.
Haematologica. 2017;102(s2):1–882 (P640).
55. Pivot X, Gligorov J, Müller V, et al. Preference for
subcutaneous or intravenous administration of
trastuzumab in patients with HER2-positive early
breast cancer (PrefHer): an open-label randomised
study. Lancet Oncol. 2013;14:962–70.
56. Rule S, Briones J, Smith R, et al. Preference for
rituximab subcutaneous (SC) and intravenous (IV)
among patients with CD20? non-Hodgkin’s lym-
phoma (NHL) completing the RASQ measure in
randomized phase III studies PREFMAB and MAB-
CUTE. Value Health. 2014;17(7):A537.
57. Lugtenburg P, Rueda A, Avivi I, et al. Patient satis-
faction with subcutaneous vs intravenous ritux-
imab combined with CHOP for untreated diffuse
large B-cell lymphoma: results from the Phase IIIb
2230 Adv Ther (2017) 34:2210–2231
MabEase study. Hematol Oncol. 2013;33(Suppl 1).
(abstract S383).
58. Rule S, Collins GP, Samanta K. Subcutaneous vs
intravenous rituximab in patients with
non-Hodgkin lymphoma: a time and motion study
in the United Kingdom. J Med Econ. 2014;17:459–68.
59. De Cock E, Kritikou P, Sandoval M, et al. Time
savings with rituximab subcutaneous injection
versus rituximab intravenous infusion: a time and
motion study in eight countries. PLoS One.
2016;11:e0157957. doi:10.1371/journal.pone.
0157957 (epub ahead of print).
60. Ponzetti C, Canciani M, Farina M, et al. Potential
resource and cost saving analysis of subcutaneous
versus intravenous administration for rituximab in
non-Hodgkin’s lymphoma and for trastuzumab in
breast cancer in 17 Italian hospitals based on a
systematic survey. Clinicoecon Outcomes Res.
2016;8:227–33.
61. Cheson BD. CLL and NHL: the end of chemother-
apy? Blood. 2014;123:3368–70.
62. Ibrutinib 140 mg hard capsules. Summary of pro-
duct characteristics. Janssen-Cilag Limited. Last
updated 5 Sept 2016. https://www.medicines.org.
uk/emc/medicine/29383. Accessed 05 Nov 2016.
63. Idelalisib 100 mg. Summary of product character-
istics. Gilead Sciences Limited. Last updated 27
September 2016. https://www.medicines.org.uk/
emc/medicine/29202. Accessed 05 Nov 2016.
64. Venetoclax tablets, for oral use. Prescribing infor-
mation. AbbVie/Roche Products Limited. Last
updated April 2016. http://www.accessdata.fda.
gov/drugsatfda_docs/label/2016/208573s000lbl.pdf.
Accessed 05 November 2016.
65. Fludarabine oral 10 mg tablet. Summary of product
characteristics. Sanofi. Last updated 14 October
2015. http://www.medicines.org.uk/emc/medicine/
4240/. Accessed 05 Nov 2016.
66. Cyclophosphamide tablets 50 mg. Baxter Health-
care. Last updated 01 April 2015. https://www.
medicines.org.uk/emc/medicine/30161. Accessed
05 Nov 2016.
67. Davies A, Mihaljevic B, Mercadal S, et al. Longer
term efficacy and safety of subcutaneous compared
with intravenous rituximab: updated results of the
phase 3 SABRINA study. Abstract presented at the
American Society of Hematology Annual Meeting
2016, Abstract 1103.
Adv Ther (2017) 34:2210–2231 2231
